Primary and secondary prevention of myocardial infarction

被引:4
作者
Borghi, C
Ambrosioni, E
机构
关键词
myocardial infarction; risk; hypertension; cholesterol; aspirin; beta-blockers; ace-inhibitors;
D O I
10.3109/10641969609088984
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The prevention of coronary artery disease (CHD) and particularly of myocardial infarction (MI) is based on some well designed strategies aimed at treating both asymptomatic high-risk patients (primary prevention) and patients with established CHD (secondary prevention). A positive impact from primary prevention can be basically achieved trough a reduction in high blood pressure and by correcting dyslipidemia. The benefit can be substantially increased by smoking cessation, increasing physical exercise, reduction of body weight, use of post-menopausal oestrogen, moderate alcohol consumption and use of high doses of vitamin E in those patients who are compliant with the specific strategies. Secondary prevention of MI can be again obtained by controlling blood pressure and reducing serum cholesterol in patients surviving acute MI who can also benefit from the administration of beta-blockers, aspirin and probably ace-inhibitors particularly in presence of left ventricular dysfunction. We suggest that in both arms of prevention, significant results can be achieved mainly by a multifactorial approach capable of correcting all the modifiable risk factors that contribute to the rather complex pathogenesis of CHD.
引用
收藏
页码:547 / 558
页数:12
相关论文
共 22 条
  • [1] [Anonymous], 1991, JAMA, V265, P3255
  • [2] ENERGY SAVINGS OF WATER-HEATER RETROFITS - EVIDENCE FROM HOOD RIVER
    BROWN, MA
    WHITE, DL
    PURUCKER, SL
    [J]. ENERGY AND BUILDINGS, 1989, 13 (01) : 51 - 61
  • [3] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [4] FANG J, 1995, J HYPERTENS, V13, P413
  • [5] HAMSTEN A, 1987, LANCET, V2, P3
  • [6] LEIZOROVICZ A, 1988, EUR HEART J, V9, P8
  • [7] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .1. PROLONGED DIFFERENCES IN BLOOD-PRESSURE - PROSPECTIVE OBSERVATIONAL STUDIES CORRECTED FOR THE REGRESSION DILUTION BIAS
    MACMAHON, S
    PETO, R
    CUTLER, J
    COLLINS, R
    SORLIE, P
    NEATON, J
    ABBOTT, R
    GODWIN, J
    DYER, A
    STAMLER, J
    [J]. LANCET, 1990, 335 (8692) : 765 - 774
  • [8] MEDICAL PROGRESS - THE PRIMARY PREVENTION OF MYOCARDIAL-INFARCTION
    MANSON, JE
    TOSTESON, H
    RIDKER, PM
    SATTERFIELD, S
    HEBERT, P
    OCONNOR, GT
    BURING, JE
    HENNEKENS, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (21) : 1406 - 1416
  • [9] 10-YEAR MORTALITY FROM CARDIOVASCULAR-DISEASE IN RELATION TO CHOLESTEROL LEVEL AMONG MEN WITH AND WITHOUT PREEXISTING CARDIOVASCULAR-DISEASE
    PEKKANEN, J
    LINN, S
    HEISS, G
    SUCHINDRAN, CM
    LEON, A
    RIFKIND, BM
    TYROLER, HA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (24) : 1700 - 1707
  • [10] EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION - RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL
    PFEFFER, MA
    BRAUNWALD, E
    MOYE, LA
    BASTA, L
    BROWN, EJ
    CUDDY, TE
    DAVIS, BR
    GELTMAN, EM
    GOLDMAN, S
    FLAKER, GC
    KLEIN, M
    LAMAS, GA
    PACKER, M
    ROULEAU, J
    ROULEAU, JL
    RUTHERFORD, J
    WERTHEIMER, JH
    HAWKINS, CM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (10) : 669 - 677